Federal Register Notice: FDA’s Peripheral and Central Nervous System Drugs Advisory Committee will meet 5/22, from 8 a.m. to 5 p.m. at the FDA White Oak Campus, 10903 New Hampshire Ave., Bldg. 31 Conference Center, the Great Room (Rm. 1503), Silver Spring, MD. The committee will discuss a Merck NDA for suvorexant tablets for insomnia characterized by difficulties with sleep onset and/or maintenance. Contact Glendolynn S. Johnson, (301) 796-9001. To view this notice, click here.